A new study from Moffit Cancer Cold Help Doctor Predict How Well Patients With a Specific Type of Lung Cancer will Respond to New Therapies. The research, Published in Clinical Cancer ResearchFound that measuring the interaction between two proteins, raf, ring provide valuable insights into the effectiveness of treatments for patients with krasg12c-malay of lung cancer knowledge for being particularly Difability to Treat.

The Findings Reveled that Tumors with Higher Levels of RAS -RAF Protein Interaction was more like to respond to krasg12c inhibitors, a class of drugs designed to target the krasg12c mutation. This Discovery Cold Help Doctor Identify which patients are most likely to benefit from this treatment.

The researchers developed a special test, called a proximity ligation assay, to measure how often ras and raf interact inseed cancer cells. Their results showed that tumors with stranger ras -raf interactions

“Our Findings BE y help doctors Make more informed decisions and provide better treatment outs for patients for patients. “

The study also compared this method with other common markers of cancer activity, like egfr, and found that egfr activity did not predict response to the krasg12c inhbitors. This sugges that ras -raf interaction is a more accurate biomarker for treatment response.

“This research opens the door to more personalized cancer treatment,” said Haura, Associate Center Director for Clinical Science at MOFFITTT. “The ability to Assess Ras Signaling Directly in Tumor Samples Bet Lead to More Targeted Therapies and Better Outcomes for Patients with Kras-Mutant Cancers.”

The new proximity ligation assay method could become an important tool in Clinical Settings, Helping Doctors Selects Selects for the Right Treatments for the Right PATINES and Improving Outcomes in a Type of Types. Atment options.